Strategic Deal Restructuring Informed by Scientific Due Diligence on an Anemia Therapeutic

Challenge: A generalist investment fund with limited experience in the pharmaceutical sector was evaluating a co-investment opportunity in an early-stage therapeutic project targeting novel...
Learn More

Due Diligence Support for High-Risk Pediatric Oncology Asset

Challenge: Our client, a private equity-backed specialty pharmaceutical company experiencing rapid growth through mergers and acquisitions, was actively evaluating several late-stage development...
Learn More

Evaluating the Commercial Viability of a Novel Neonatal Therapy Approach

Challenge: A leading U.S. children’s hospital commissioned an independent review of a novel therapeutic approach for rare neonatal diseases. The principal investigator (PI) - a highly regarded,...
Learn More

Landscape Assessment of Novel Pain Targets for R&D Prioritization

Challenge: A privately held US-based biotech company specializing in pain therapeutics had developed a cutting-edge drug discovery platform utilizing multi-omic, tissue-specific datasets. This...
Learn More

TTO Strategic IP Portfolio Review

Synopsis For Technology Transfer Offices (TTOs), evaluating and prioritizing intellectual property (IP) portfolios is a critical step in determining the best allocation of internal funding and...
Learn More

Axl/merTK target assessment for an AI-driven drug discovery company

Challenge: An AI-driven drug discovery company requested an expert third party assessment of the attractiveness and risks of a particular discovery strategy focused on a dual tyrosine kinase...
Learn More

Technical Feasibility Ranking of Gene Therapies for CNS Diseases

Challenge: A mid-sized pharmaceutical company was considering the option of expanding into developing gene therapies for CNS diseases. Alacrita was asked to help them evaluate and prioritize the...
Learn More

Scouting for assets discontinued from development due to neutralizing antibodies (Nabs)

Challenge: An early-stage biotech company asked Alacrita to identify drug program assets that had been discontinued from further development due to neutralizing antibodies (Nabs) but not due to...
Learn More

Identiying molecules for novel formulation technology

Challenge A company had developed a technology for overcoming solubility issues in drug formulations and was planning to develop a small number of 505 (b)(2) candidate molecules. The client had...
Learn More

Revamped corporate pitch deck and partnering deal terms for European biotech

Project Challenge: A European biotech company was developing next-generation ADC payloads with at least as good intracellular cytotoxicity properties as other payloads used in ADCs, but with a much...
Learn More

Asset scouting for novel injectable formulations for large pharma

Challenge: A public, multi-national pharmaceutical company historically focused on producing generics (including branded), active pharmaceuticals ingredients, biologics, and over the counter...
Learn More

In-Licensing Support and Asset Scouting in CNS

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...
Learn More